GlassScriptPhysician profile
Jose J Pinto
NPI 1982643045
$8,651.06
in general payments reported to CMS, 2019-2025
31 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $1,854 · 2021: $2,130 · 2022: $989 · 2023: $827 · 2024: $366 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.59 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $4,521.54 | 2019-2021 | |
| Abbvie INC. | $452.85 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $426.36 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $327.26 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $301.86 | 2019-2025 | Slynd, Tyblume |
| Mayne Pharma Commercial LLC | $266.05 | 2021-2023 | |
| Astellas Pharma US INC | $249.05 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $228.32 | 2021-2022 | |
| Millicent US INC | $197.04 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Amag Pharmaceuticals, INC. | $193.83 | 2019-2020 | |
| Therapeuticsmd, INC. | $171.43 | 2019-2022 | |
| Pfizer INC. | $146.26 | 2019-2023 | |
| Coopersurgical, INC. | $124.78 | 2020-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $120.01 | 2019-2023 | Gardasil 9 |
| Scynexis, INC. | $119.72 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $111.82 | 2019-2021 | |
| Evofem Biosciences, INC. | $106.79 | 2022-2025 | Phexxi, Solosec, Phexx |
| Allergan, INC. | $97.28 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.63 | 2019-2024 | |
| Mylan Pharmaceuticals INC. | $73.39 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $51.16 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.00 | 2024 | Xifaxan, Trulance |
| Becton, Dickinson and Company | $38.52 | 2021-2022 | |
| Mycovia Pharmaceuticals, INC. | $29.21 | 2022-2023 | Vivjoa |
| Lupin INC. | $27.05 | 2019-2020 | |
| Organon LLC | $26.81 | 2022-2024 | |
| Avion Pharmaceuticals | $26.59 | 2021-2022 | |
| Exact Sciences Corporation | $25.22 | 2025 | The Cologuard Plus Collection Kit |
| Sage Therapeutics, LLC | $15.98 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $15.73 | 2019 | |
| Duchesnay USA Incorporated | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.